Survival Extended With Pembrolizumab/Chemotherapy in Esophageal Cancer
Ken Kato, MD discusses the outcomes of the phase 3 KEYNOTE-590 study on esophageal cancer.
Ken Kato, MD, of the National Cancer Center Hospital in Tokyo, Japan discusses the outcomes of the phase 3 KEYNOTE-590 study on esophageal cancer.
The results, which were presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2020, evaluated the efficacy of pembrolizumab plus chemotherapy versus chemotherapy alone as first-line treatment of patients with advanced esophageal cancer. The combination demonstrated improvements were seen in both progression-free survival and overall survival.
According to Kato, the safety profile was manageable. The confirmed overall response rate was 45% for the combination and 29.3% for the chemotherapy alone. The rate adverse effects for the combination was slightly higher for the combination, 72% and 68% for chemotherapy alone. The rate of discontinuation from drug-related adverse events was 19% for the combination and 12% for the chemotherapy alone.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
